
## **NOVARTIS AG**

ISIN: CH0012005267 WKN: 1200526

### Overview





Information about previous performance does not guarantee future performance. **Source:** FactSet

### **Recent research**

on instrument	on sector	on market	
Date		Headline	Download
2024/07/24	80.   526 921   120	Global Equity Ratings	
2024/07/12	86. July 87 176	Global Equity Ratings	
2024/06/21	80.   526 921   120	Global Equity Ratings	
2024/06/14	86. July 87 176	Global Equity Ratings	
2024/05/29	80.   526 821   120	Global Equity Ratings	




# **Details**



-
-
80.34 EUR
80.34 EUR
79.94 EUR
80.38 EUR
80.2248 EUR
1,589
127,477.20
13
62

Performance ar	nd Risk		
	6m	1Y	3Y
Perf (%)	-	-	-
Perf (abs.)	-	-	-
Beta	0.93	0.89	0.80
Volatility	-	-	-



Information about previous performance does not guarantee future performance. **Source:** FactSet

Price data	
Ø price 5 days   Ø volume 5 days (pcs.)	- EUR (-)
Ø price 30 days   Ø volume 30 days (pcs.)	- EUR (-)
Ø price 100 days   Ø volume 100 days (pcs.)	- EUR (-)
Ø price 250 days   Ø volume 250 days (pcs.)	- EUR (-)
YTD High   date	- EUR (-)
YTD Low   date	- EUR (-)
52 Weeks High   date	- EUR (-)
52 Weeks Low   date	- EUR (-)

All listings for NOVARTIS AG	3				
Exchange 🕏	Date	Time	Price	Trading volume (mio.)	Number of trades
SIX Swiss Exchange	2024/ 07/26	17:30	97.45 CHF	263.95	12,739
London Stock Exchange European Trade Reporting	2024/ 07/26	17:20	97.005 CHF	0.63	15
Hanover	2019/ 06/28	08:01	80.10 EUR	0.00	2
Hamburg	2019/ 06/28	14:05	80.19 EUR	0.08	4



Frankfurt	2019/ 06/28	19:57	80.16 EUR	0.13	13
FINRA other OTC Issues	2024/ 07/26	17:33	106.974 USD	0.04	3
Duesseldorf	2019/ 06/28	14:08	80.18 EUR	0.00	2
Berlin	2019/ 06/28	18:45	80.40 EUR	0.00	16



# Company profile

### **Company Logo**



### **Contact Details**

**NOVARTIS AG** 

- -

Lichtstrasse 35 - 4056 Basel Telefon: +41-61-324-11-11

Fax: + E-mail: -

#### **PDF Downloads**

Company report: NOVARTIS AG

### **Company Profile**

ф,

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Members of Man	agement Board
Vasant (Vas) Narasimhan	Chairman of Managing Board
Klaus Moosmayer	Member of Executive Committee
Steffen Lang	Member of Executive Committee
Aharon Gal	Member of Executive Committee
Fiona H. Marshall	Member of Executive Committee
Harry Kirsch	Member of Executive Committee
Karen Hale	Member of Executive Committee
Kees Roks	Member of Executive Committee
Lutz Hegemann	Member of Executive Committee
Michelle Weese	Member of Executive Committee
Patrick Horber	Member of Executive Committee
Rob Kowalski	Member of Executive Committee
Shreeram Aradhye	Member of Executive Committee
Victor Bulto	Member of Executive Committee

Board of dire	ctors
Charles Sawyers	Member of the administrative board
Nancy Andrews	Member of the administrative board
Simon Moroney	Member of the administrative board
Ana de Pro Gonzalo	Member of the administrative board
Bridgette Heller	Member of the administrative board
Daniel Hochstrasser	Member of the administrative board
Frans van Houten	Member of the administrative board
John Young	Member of the administrative board
Mary Doherty	Member of the administrative board
Patrice Bula	Member of the administrative board
Ton Büchner	Member of the administrative board
William Winters	Member of the administrative board
Hans Jörg Reinhardt	Chairman of the administrative boar

